- Home
- CELH vs JAZZ Comparison
CELH vs JAZZ Comparison
Compare CELH & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELH
- JAZZ
- Stock Information
- Founded
- CELH 2004
- JAZZ 2003
- Country
- CELH United States
- JAZZ Ireland
- Employees
- CELH N/A
- JAZZ N/A
- Industry
- CELH Beverages (Production/Distribution)
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CELH Consumer Staples
- JAZZ Health Care
- Exchange
- CELH Nasdaq
- JAZZ Nasdaq
- Market Cap
- CELH 7.5B
- JAZZ 6.1B
- IPO Year
- CELH N/A
- JAZZ 2007
- Fundamental
- Price
- CELH $36.74
- JAZZ $110.80
- Analyst Decision
- CELH Buy
- JAZZ Strong Buy
- Analyst Count
- CELH 17
- JAZZ 13
- Target Price
- CELH $47.00
- JAZZ $187.15
- AVG Volume (30 Days)
- CELH 7.6M
- JAZZ 1.4M
- Earning Date
- CELH 05-06-2025
- JAZZ 05-05-2025
- Dividend Yield
- CELH N/A
- JAZZ N/A
- EPS Growth
- CELH N/A
- JAZZ 41.75
- EPS
- CELH 0.45
- JAZZ 8.65
- Revenue
- CELH $1,355,630,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- CELH $42.37
- JAZZ $7.60
- Revenue Next Year
- CELH $17.56
- JAZZ $3.43
- P/E Ratio
- CELH $81.06
- JAZZ $12.82
- Revenue Growth
- CELH 2.85
- JAZZ 6.12
- 52 Week Low
- CELH $21.10
- JAZZ $95.49
- 52 Week High
- CELH $98.85
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CELH 57.71
- JAZZ 46.16
- Support Level
- CELH $34.78
- JAZZ $103.51
- Resistance Level
- CELH $39.16
- JAZZ $104.53
- Average True Range (ATR)
- CELH 2.28
- JAZZ 5.88
- MACD
- CELH -0.28
- JAZZ 1.19
- Stochastic Oscillator
- CELH 61.09
- JAZZ 84.82
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.